CG Oncology, Inc. Common stock CGON
i
Market dataready · fetched 2026-11-13T01:26:12.583Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:41:22.935766425Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T01:26:12.123025+00:00
CG Oncology, Inc. Common stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 101.96 | 242.0% | 47.1% | 53.20 | 325.0% | 31.8% |
| 25Δ | 96.45 | 244.6% | 40.5% | 58.07 | 300.4% | 26.5% |
| 30Δ | 92.40 | 253.3% | 36.2% | 62.16 | 286.4% | 22.6% |
| 35Δ | 88.20 | 257.1% | 31.6% | 65.97 | 278.6% | 19.5% |
| 40Δ | 83.71 | 254.9% | 26.8% | 69.74 | 284.0% | 17.3% |
| 45Δ | 80.44 | 263.4% | 24.1% | 73.36 | 277.8% | 14.9% |
| 50Δ | 76.74 | 265.6% | 20.7% | 77.10 | 273.5% | 12.7% |
| 55Δ | 72.93 | 258.9% | 17.0% | 80.95 | 271.6% | 10.8% |
| 60Δ | 69.20 | 254.4% | 13.6% | 84.84 | 269.7% | 9.0% |
| 65Δ | 65.86 | 277.8% | 12.4% | 88.07 | 257.0% | 7.3% |
| 70Δ | 62.25 | 283.5% | 10.2% | 91.76 | 247.6% | 5.7% |
| 75Δ | 58.54 | 281.3% | 7.8% | 96.64 | 245.9% | 4.4% |
| 80Δ | 54.77 | 277.6% | 5.7% | 102.41 | 244.6% | 3.3% |
20Δ
- Pseudo strike
- 101.96
- IV
- 242.0%
- B/E move
- 47.1%
- Pseudo strike
- 53.20
- IV
- 325.0%
- B/E move
- 31.8%
25Δ
- Pseudo strike
- 96.45
- IV
- 244.6%
- B/E move
- 40.5%
- Pseudo strike
- 58.07
- IV
- 300.4%
- B/E move
- 26.5%
30Δ
- Pseudo strike
- 92.40
- IV
- 253.3%
- B/E move
- 36.2%
- Pseudo strike
- 62.16
- IV
- 286.4%
- B/E move
- 22.6%
35Δ
- Pseudo strike
- 88.20
- IV
- 257.1%
- B/E move
- 31.6%
- Pseudo strike
- 65.97
- IV
- 278.6%
- B/E move
- 19.5%
40Δ
- Pseudo strike
- 83.71
- IV
- 254.9%
- B/E move
- 26.8%
- Pseudo strike
- 69.74
- IV
- 284.0%
- B/E move
- 17.3%
45Δ
- Pseudo strike
- 80.44
- IV
- 263.4%
- B/E move
- 24.1%
- Pseudo strike
- 73.36
- IV
- 277.8%
- B/E move
- 14.9%
50Δ
- Pseudo strike
- 76.74
- IV
- 265.6%
- B/E move
- 20.7%
- Pseudo strike
- 77.10
- IV
- 273.5%
- B/E move
- 12.7%
55Δ
- Pseudo strike
- 72.93
- IV
- 258.9%
- B/E move
- 17.0%
- Pseudo strike
- 80.95
- IV
- 271.6%
- B/E move
- 10.8%
60Δ
- Pseudo strike
- 69.20
- IV
- 254.4%
- B/E move
- 13.6%
- Pseudo strike
- 84.84
- IV
- 269.7%
- B/E move
- 9.0%
65Δ
- Pseudo strike
- 65.86
- IV
- 277.8%
- B/E move
- 12.4%
- Pseudo strike
- 88.07
- IV
- 257.0%
- B/E move
- 7.3%
70Δ
- Pseudo strike
- 62.25
- IV
- 283.5%
- B/E move
- 10.2%
- Pseudo strike
- 91.76
- IV
- 247.6%
- B/E move
- 5.7%
75Δ
- Pseudo strike
- 58.54
- IV
- 281.3%
- B/E move
- 7.8%
- Pseudo strike
- 96.64
- IV
- 245.9%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 54.77
- IV
- 277.6%
- B/E move
- 5.7%
- Pseudo strike
- 102.41
- IV
- 244.6%
- B/E move
- 3.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 101.63% | |
| 103.80% | |
| 104.90% | |
| 103.39% | |
| 101.25% | |
| 103.17% | |
| 101.26% | |
| 102.98% | |
| 102.17% | |
| 105.99% |
Biotechnology
CHRS
Description unavailable
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →CMPX
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The…
More →CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe…
More →